Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Heidelberg Pharma AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Telix Pharma Enters into Licensing Agreement with Wilex 12
Magenta Therapeutics Enters into Multi-Target Research Agreement with Heidelberg Pharma 13
Heidelberg Pharma Enters into Research Agreement with Takeda Pharma 14
Nordic Nanovector Enters into Research Agreement with Heidelberg Pharma 15
Heidelberg Pharma Enters into Agreement with Celonic 16
Advanced Proteome Therapeutics Enters into Agreement with Heidelberg Pharma 17
MabVax Therapeutics Enters into Co-Development Agreement with Heidelberg Pharma 18
Licensing Agreements 19
Magenta Therapeutics Enters into Licensing Agreement with Heidelberg Pharma 19
Heidelberg Pharma Enters into Licensing Agreement with University of Texas MD Anderson Cancer Center 20
Heidelberg Pharma Exercises Option for Licensing Agreement with Max Delbruck Center 21
RedHill Biopharma Enters into Licensing Agreement with Wilex for Mesupron 22
Wilex Enters Into Licensing Agreement With Link Health For Mesupron 23
Equity Offering 24
Heidelberg Pharma Raises USD22.8 Million in Rights Offering of Shares 24
Wilex Raises USD5.4 Million in Rights Offering of Shares 25
Wilex to Raise USD4.7 Million in Rights Offering of Shares 26
Wilex Raises USD1.81 Million in Private Placement of Shares 27
Wilex Raises USD0.86 Million in Rights Offering of Shares 28
Wilex Raises USD4.4 Million in Right Issue of Shares 29
Wilex Completes Private Placement Of Shares For US$12.4 Million 30
Wilex Completes Rights Offering Of Shares For US$7.8 Million 31
Wilex Completes Rights Offering Of Shares For US$12.6 Million 32
Debt Offering 33
Heidelberg Pharma Raises USD17.5 Million in Private Placement of Bonds 33
Asset Transactions 34
UCB Pharma Re-Acquires Rights For Antibody Program From Wilex For Non-Oncology Indications 34
Heidelberg Pharma AG – Key Competitors 35
Heidelberg Pharma AG – Key Employees 36
Heidelberg Pharma AG – Locations And Subsidiaries 37
Head Office 37
Other Locations & Subsidiaries 37
Recent Developments 38
Financial Announcements 38
Oct 11, 2018: Heidelberg Pharma AG: Interim management statement on the first nine months of 2018 38
Jul 12, 2018: Heidelberg Pharma reports on first half -year 40
Apr 12, 2018: Heidelberg Pharma: Interim Management Statement on the First Three Months of 2018 42
Mar 22, 2018: Heidelberg Pharma announces financial figures for fiscal year 2017 and provides business update 44
Oct 09, 2017: WILEX: Interim management statement for the first nine months of 2017 47
Jul 13, 2017: WILEX reports on first half-year 50
Apr 12, 2017: WILEX: Interim management statement on the first three months of 2017 52
Mar 30, 2017: WILEX announces financial figures for the 2016 fiscal year and reports on course of business 54
Product News 56
01/24/2017: Antibody against bone marrow tumor developed at MDC is put into application 56
Product Approvals 57
Oct 20, 2017: RedHill Biopharma Receives FDA Orphan Drug Designation for MESUPRON for Pancreatic Cancer 57
Clinical Trials 58
Nov 13, 2017: Heidelberg Pharma announces results from research collaboration with Heidelberg University and the DKFZ to be presented at ASH Annual Meeting 58
Oct 19, 2017: RedHill Biopharma Announces Poster Presentation at the 2017 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference 59
Sep 20, 2017: WILEX: Subsidiary Heidelberg Pharma to Present the Proprietary ATAC Technology Platform at the Annual World ADC Summit 60
Sep 18, 2017: RedHill Biopharma Receives Notice of Allowance for a New U.S. Patent Covering use of MESUPRON in Combination Therapy for cancers 61
Other Significant Developments 62
Oct 19, 2018: WILEX successfully completes change of name to Heidelberg Pharma 62
Appendix 63
Methodology 63
About GlobalData 63
Contact Us 63
Disclaimer 63
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Heidelberg Pharma AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Heidelberg Pharma AG, Deals By Therapy Area, 2012 to YTD 2018 9
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Telix Pharma Enters into Licensing Agreement with Wilex 12
Magenta Therapeutics Enters into Multi-Target Research Agreement with Heidelberg Pharma 13
Heidelberg Pharma Enters into Research Agreement with Takeda Pharma 14
Nordic Nanovector Enters into Research Agreement with Heidelberg Pharma 15
Heidelberg Pharma Enters into Agreement with Celonic 16
Advanced Proteome Therapeutics Enters into Agreement with Heidelberg Pharma 17
MabVax Therapeutics Enters into Co-Development Agreement with Heidelberg Pharma 18
Magenta Therapeutics Enters into Licensing Agreement with Heidelberg Pharma 19
Heidelberg Pharma Enters into Licensing Agreement with University of Texas MD Anderson Cancer Center 20
Heidelberg Pharma Exercises Option for Licensing Agreement with Max Delbruck Center 21
RedHill Biopharma Enters into Licensing Agreement with Wilex for Mesupron 22
Wilex Enters Into Licensing Agreement With Link Health For Mesupron 23
Heidelberg Pharma Raises USD22.8 Million in Rights Offering of Shares 24
Wilex Raises USD5.4 Million in Rights Offering of Shares 25
Wilex to Raise USD4.7 Million in Rights Offering of Shares 26
Wilex Raises USD1.81 Million in Private Placement of Shares 27
Wilex Raises USD0.86 Million in Rights Offering of Shares 28
Wilex Raises USD4.4 Million in Right Issue of Shares 29
Wilex Completes Private Placement Of Shares For US$12.4 Million 30
Wilex Completes Rights Offering Of Shares For US$7.8 Million 31
Wilex Completes Rights Offering Of Shares For US$12.6 Million 32
Heidelberg Pharma Raises USD17.5 Million in Private Placement of Bonds 33
UCB Pharma Re-Acquires Rights For Antibody Program From Wilex For Non-Oncology Indications 34
Heidelberg Pharma AG, Key Competitors 35
Heidelberg Pharma AG, Key Employees 36
Heidelberg Pharma AG, Subsidiaries 37
List of Figures
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9